Nanoparticle therapeutics: an emerging treatment modality for cancer

Mark E. Davis,Zhuo (Georgia) Chen,Dong M. Shin,Zhuo Chen
DOI: https://doi.org/10.1038/nrd2614
IF: 112.288
2008-09-01
Nature Reviews Drug Discovery
Abstract:Key PointsNanoparticles are emerging as a new class of therapeutics for cancer because they can perform in ways that other therapeutic modalities cannot.Newer nanoparticle therapeutics are showing enhanced efficacy with lower side effects than traditional small-molecule chemotherapeutics in early clinic studies, and are doing so without creating additional new side effects due to the nanoparticle.Although there are many types of nanoparticles, few will have the proper attributes to reach clinical use because of the issues involved in translating research grade nanoparticles to clinic grade nanoparticles.Newer nanoparticle therapeutics have a greater degree of multifunctionality and involve not only delivery to the tumour but intracellular delivery so that multidrug resistance can be bypassed and therapeutic agents such as siRNA that require intracellular delivery can be utilized.Nanoparticles that contain cancer cell-surface targeting ligands are now in the clinic.
pharmacology & pharmacy,biotechnology & applied microbiology
What problem does this paper attempt to address?